We Offer Worldwide Shipping
Login Wishlist

1-O-Cinnamoyltrichilinin

$954

  • Brand : BIOFRON

  • Catalogue Number : BN-O1496

  • Specification : 98%(HPLC)

  • CAS number : 117869-72-4

  • Formula : C39H46O9

  • Molecular Weight : 658.78

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1496

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

658.78

Appearance

Botanical Source

Structure Type

Category

SMILES

Synonyms

IUPAC Name

Density

Solubility

Flash Point

Boiling Point

Melting Point

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:117869-72-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

18475821

Abstract

The biological activity of eight 1-oxa-4-aza-2-silacyclanes with the OSiCH2N fragment including 6-membered 2-sila-5-morpholinones (1-3) and 4-acyl-2-silamorpholines (4-6)and previously unknown 7-membered derivatives of salicylic acid (7, 8) was studied. Compounds 1 and 3-6 show the certain antihypoxic action. Compounds 2 (40 mg/kg), 4 (20 mg/kg), 6 (40 mg/kg), 7 (20 mg/kg) and 8 (40 mg/kg) reduce the physical serviceability of intact animals. Compound 1 (20 mg/kg) influences the physical serviceability in a moderate-positive way on the background of chlorophos-poisoning. Compounds 5-8 displayed protective properties against chlorophos-poisoning at the LD50 dose and compounds 2, 4, 5, 7 at the LD100 dose. Influence of compounds 1 and 2 on the emotional-research behavior of mice was studied.

Title

Six- and Seven-Membered 1-Oxa-4-Aza-2-Silacyclanes as Possible Correctors of Adaptational Mechanisms

Author

Andrey V. Kurochka, Ol'ga V. Agafonova, Aleksandr S. Losev, Elizaveta A. Mamaeva, Sergey Yu. Bylikin, Vadim V. Negrebetsky, Evgeniya P. Kramarova, Aleksandr G. Shipov, Yuri I. Baukov

Publish date

1998;

PMID

25849383

Abstract

Background
Psychological stress has been associated with transient global amnesia (TGA). Whether a cancer diagnosis, a severely stressful life event, is associated with subsequent risk of TGA has not been studied.

Methods
Based on the Swedish Cancer Register and Patient Register, we conducted a prospective cohort study including 5,365,608 Swedes at age 30 and above during 2001-2009 to examine the relative risk of TGA among cancer patients, as compared to cancer-free individuals. Incidence rate ratios (IRRs) and their 95% confidence intervals (CIs) derived from Poisson regression were used as estimates of the association between cancer diagnosis and the risk of TGA.

Results
During the study 322,558 individuals (6.01%) received a first diagnosis of cancer. We identified 210 cases of TGA among the cancer patients (incidence rate, 0.22 per 1000 person-years) and 4,887 TGA cases among the cancer-free individuals (incidence rate, 0.12 per 1000 person-years). Overall, after adjustment for age, sex, calendar year, socioeconomic status, education and civil status, cancer patients had no increased risk of TGA than the cancer-free individuals (IRR, 0.99; 95% CI, 0.86-1.13). The IRRs did not differ over time since cancer diagnosis or across individual cancer types. The null association was neither modified by sex, calendar period or age.

Conclusion
Our study did not provide support for the hypothesis that patients with a new diagnosis of cancer display a higher risk of TGA than cancer-free individuals.

Title

Is a Cancer Diagnosis Associated with Subsequent Risk of Transient Global Amnesia?

Author

Jianwei Zhu, Donghao Lu, Olafur Sveinsson, Karin Wirdefeldt, Katja Fall, Fredrik Piehl, Unnur Valdimarsdottir, Fang Fang

Publish date

2015

PMID

24473341

Abstract

Development of a vaccine against congenital infection with human cytomegalovirus is complicated by the issue of re-infection, with subsequent vertical transmission, in women with pre-conception immunity to the virus. The study of experimental therapeutic prevention of re-infection would ideally be undertaken in a small animal model, such as the guinea pig cytomegalovirus (GPCMV) model, prior to human clinical trials. However, the ability to model re-infection in the GPCMV model has been limited by availability of only one strain of virus, the 22122 strain, isolated in 1957. In this report, we describe the isolation of a new GPCMV strain, the CIDMTR strain. This strain demonstrated morphological characteristics of a typical Herpesvirinae by electron microscopy. Illumina and PacBio sequencing demonstrated a genome of 232,778 nt. Novel open reading frames ORFs not found in reference strain 22122 included an additional MHC Class I homolog near the right genome terminus. The CIDMTR strain was capable of dissemination in immune compromised guinea pigs, and was found to be capable of congenital transmission in GPCMV-immune dams previously infected with salivary gland‑adapted strain 22122 virus. The availability of a new GPCMV strain should facilitate study of re-infection in this small animal model.

KEYWORDS

guinea pig cytomegalovirus, cytomegalovirus strain variation, CMV immune evasion, congenital cytomegalovirus infection, congenital CMV vaccines

Title

Molecular and Biological Characterization of a New Isolate of Guinea Pig Cytomegalovirus

Author

Mark R. Schleiss,1,* Shane McAllister,1 Anibal G. Armien,2 Nelmary Hernandez-Alvarado,1 Claudia Fernandez-Alarcon,1 Jason C. Zabeli,1 Thiruvarangan Ramaraj,3 John A. Crow,3 and Michael A. McVoy4

Publish date

2014 Feb


Description :

Empty ...